Patents by Inventor Jay M. Matthews

Jay M. Matthews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxypyridoxazepines as NRF2 activators
    Patent number: 11945826
    Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 2, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
  • Chemical Compounds
    Publication number: 20230416287
    Abstract: Provided are compounds and pharmaceutical compositions and uses thereof for inhibiting Nav1.8 voltage-gated sodium ion channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases, and cardiovascular diseases.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 28, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Jie GUANG, Jay M. MATTHEWS, Alan T. PRICE, Jared Troy SPLETSTOSER
  • HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS
    Publication number: 20220204526
    Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 30, 2022
    Inventors: Mark ELBAN, Michal Pawel GLOGOWSKI, Michael Clinton KOETTING, Brian Griffin LAWHORN, Jay M. MATTHEWS, Jaclyn Renee PATTERSON
  • TRPV4 antagonists
    Patent number: 11260049
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 1, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Peng Li, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm
  • TRPV4 antagonists
    Patent number: 11229623
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • TRPV4 ANTAGONISTS
    Publication number: 20210299113
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: September 30, 2021
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Peng LI, Jay M. MATTHEWS, John Jeffrey McATEE, Joseph E. PERO, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM
  • NRF2 activators
    Patent number: 11028099
    Abstract: The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 8, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Carl A. Brooks, Jay M. Matthews
  • TRPV4 ANTAGONISTS
    Publication number: 20200261411
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 20, 2020
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Linda S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jaclyn R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • TRPV4 antagonists
    Patent number: 10588891
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • TRPV4 antagonists
    Patent number: 10590077
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian W. Budzik, Brian Griffin Lawhorn, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, David J. Behm
  • NRF2 ACTIVATORS
    Publication number: 20200031846
    Abstract: The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
    Type: Application
    Filed: December 11, 2017
    Publication date: January 30, 2020
    Inventors: Carl A. BROOKS, Jay M. MATTHEWS
  • TRPV4 ANTAGONISTS
    Publication number: 20190216774
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 18, 2019
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian Griffin LAWHORN, Guosen YE, Lisa S. BARTON, Brian W. BUDZIK, Jay M. MATTHEWS, John Jeffrey McATEE, Jacyln R. PATTERSON, Joseph E. PERO, Robert SANCHEZ, Matthew Robert SENDER, Lamont Roscoe TERRELL, David J. BEHM, James V. THOMAS
  • TRPV4 ANTAGONISTS
    Publication number: 20190202784
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 4, 2019
    Inventors: Edward J. BRNARDIC, Carl A. BROOKS, Brian W. BUDZIK, Brian Griffin LAWHORN, Jay M. MATTHEWS, John Jeffrey McATEE, Joseh E. PERO, David J. BEHM
  • Sulfonamides as TRPM8 modulators
    Patent number: 9434711
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shawn T Branum, Raymond W Colburn, Scott L Dax, Christopher M Flores, Michele C Jetter, Yi Liu, Donald Ludovici, Mark J Macielag, Jay M Matthews, James J McNally, Laura M Andraka, Ronald K Russell, Ning Qin, Christopher Teleha, Kenneth M Wells, Scott C Youells, Mark A Youngman
  • Sulfamides as TRPM8 modulators
    Patent number: 9233947
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: January 12, 2016
    Assignee: Janssen Pharmaceutica, NV
    Inventor: Jay M Matthews
  • Cold menthol receptor-1 antagonists
    Patent number: 9090639
    Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Raymond W Colburn, Scott L Dax, Christopher M Flores, Jay M Matthews, Ning Qin, Laura W. Andraka, Christopher Teleha, Mark A Youngman
  • Imidazo[1,2-?]pyridine sulfonamides as TRPM8 modulators
    Patent number: 9067935
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, and are defined herein.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 30, 2015
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Mark J Macielag, Mingde Xia, James J McNally, Jay M Matthews
  • SULFONAMIDES AS TRPM8 MODULATORS
    Publication number: 20140315899
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Andraka, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • SULFAMIDES AS TRPM8 MODULATORS
    Publication number: 20140243329
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventor: Jay M Matthews
  • Sulfonamides as TRPM8 modulators
    Patent number: 8809327
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Reaney, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman